Prelude Stock

Prelude delivers actionable tools to manage early stage breast cancer with the DCIS test that enables personalized treatment.

Sign up today and learn more about Prelude Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Prelude Stock

PreludeDx was founded with the goal of providing better decision-making tools to breast cancer patients and physicians. Founded in 2009 with technology licensed from the University of California San Francisco, PreludeDx has focused on developing breast cancer tools that will impact a patient’s treatment decision. Their mission is to provide tools that improve patient outcomes in breast cancer and reduce the overall cost burden to the healthcare system.

Funding History

February 2016$2.1M
March 2022$20.0M


Board of Director

Alejandro Sanchez

Chief Commercial Officer

Edwin Hendrick


Andy Wade


Dan Forche


EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: